IL268361A - Therapeutic immunomodulatory mRNA preparations encoding oncogenic mutation peptides - Google Patents
Therapeutic immunomodulatory mRNA preparations encoding oncogenic mutation peptidesInfo
- Publication number
- IL268361A IL268361A IL268361A IL26836119A IL268361A IL 268361 A IL268361 A IL 268361A IL 268361 A IL268361 A IL 268361A IL 26836119 A IL26836119 A IL 26836119A IL 268361 A IL268361 A IL 268361A
- Authority
- IL
- Israel
- Prior art keywords
- oncogene mutation
- immunomodulatory therapeutic
- activating oncogene
- compositions encoding
- therapeutic mrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453465P | 2017-02-01 | 2017-02-01 | |
| US201762467063P | 2017-03-03 | 2017-03-03 | |
| US201762490523P | 2017-04-26 | 2017-04-26 | |
| US201762541571P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/016510 WO2018144775A1 (en) | 2017-02-01 | 2018-02-01 | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL268361A true IL268361A (en) | 2019-09-26 |
Family
ID=61244714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268361A IL268361A (en) | 2017-02-01 | 2019-07-30 | Therapeutic immunomodulatory mRNA preparations encoding oncogenic mutation peptides |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190351039A1 (enExample) |
| EP (1) | EP3576780A1 (enExample) |
| JP (2) | JP2020514321A (enExample) |
| KR (1) | KR20190110612A (enExample) |
| CN (2) | CN110430894A (enExample) |
| AU (1) | AU2018214556A1 (enExample) |
| BR (1) | BR112019015797A2 (enExample) |
| CA (1) | CA3051252A1 (enExample) |
| CL (1) | CL2019002134A1 (enExample) |
| CO (1) | CO2019009234A2 (enExample) |
| EA (1) | EA201991804A1 (enExample) |
| IL (1) | IL268361A (enExample) |
| MX (2) | MX2019009070A (enExample) |
| SG (1) | SG11201906969PA (enExample) |
| WO (1) | WO2018144775A1 (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017049245A2 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| MA46080A (fr) | 2015-10-22 | 2019-07-10 | Modernatx Inc | Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv) |
| EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
| ES2913626T5 (en) | 2015-12-22 | 2025-05-12 | Modernatx Inc | Compounds and compositions for intracellular delivery of agents |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| EA201991804A1 (ru) | 2017-02-01 | 2020-02-07 | МОДЕРНАТиЭкс, ИНК. | ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ |
| US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3596041B1 (en) * | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| AU2019216307A1 (en) * | 2018-01-30 | 2020-07-09 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
| KR20210018323A (ko) | 2018-06-06 | 2021-02-17 | 매사추세츠 인스티튜트 오브 테크놀로지 | 진핵 세포에서의 번역을 위한 원형 rna |
| EP3827261A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| AU2019338557A1 (en) * | 2018-09-13 | 2021-03-25 | Modernatx, Inc. | Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders |
| AU2019345104B2 (en) * | 2018-09-18 | 2025-06-12 | Universiteit Gent | Therapeutic nanoparticles and methods of use thereof |
| JP7526168B2 (ja) | 2018-09-19 | 2024-07-31 | モデルナティエックス インコーポレイテッド | Ｐｅｇ脂質及びそれらの使用 |
| US12383508B2 (en) | 2018-09-19 | 2025-08-12 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| TW202039534A (zh) * | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| SG11202108459QA (en) * | 2019-02-27 | 2021-09-29 | Actym Therapeutics Inc | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| WO2020237227A1 (en) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4041400B1 (en) * | 2019-10-09 | 2025-02-26 | Translate Bio, Inc. | Messenger rnas encoding sting and il-12 and use in the treatment of cancer |
| US20240158458A1 (en) * | 2019-10-15 | 2024-05-16 | Moderna TX, Inc. | Mrnas encoding immune modulating polypeptides and uses thereof |
| JP2023501539A (ja) * | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| BR112022009429A2 (pt) * | 2019-11-15 | 2022-08-09 | Daiichi Sankyo Co Ltd | Vacina de partícula lipídica de ácido nucleico encapsulando o mrna de hpv |
| WO2021113777A2 (en) | 2019-12-04 | 2021-06-10 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| KR102410556B1 (ko) * | 2020-01-16 | 2022-06-20 | 아주대학교산학협력단 | 미토콘드리아 타겟팅용 펩타이드 |
| EP4096720A2 (en) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| CN111440825A (zh) * | 2020-04-07 | 2020-07-24 | 嘉晨西海(杭州)生物技术有限公司 | 一种脂质体载mRNA的方法 |
| GB2632564B (en) * | 2020-04-09 | 2025-06-18 | Verve Therapeutics Inc | Base editing of angptl3 and methods of using same for treatment of disease |
| WO2021204179A1 (en) * | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| KR20220109444A (ko) | 2020-04-24 | 2022-08-04 | 주식회사 제넥신 | 자궁경부암 치료방법 |
| AU2021271317A1 (en) | 2020-05-15 | 2023-01-19 | Crispr Therapeutics Ag | Messenger RNA encoding Cas9 for use in genome-editing systems |
| AU2021326420A1 (en) * | 2020-07-31 | 2023-03-09 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
| WO2022031021A1 (ko) * | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN116917470A (zh) * | 2020-10-14 | 2023-10-20 | 达冕生物有限公司 | PAN-RAS mRNA癌症疫苗 |
| IL302215A (en) | 2020-10-20 | 2023-06-01 | St Pharm Co Ltd | Oligonucleotide for 5'-capped rna synthesis |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| CA3202227A1 (en) * | 2020-11-20 | 2022-05-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| WO2022140252A1 (en) * | 2020-12-21 | 2022-06-30 | Beam Therapeutics Inc. | Nanomaterials comprising ester-linked acetals |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| CN116867799A (zh) * | 2021-02-10 | 2023-10-10 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
| EP4301405A4 (en) * | 2021-03-05 | 2025-01-29 | ModernaTX, Inc. | ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP) |
| JP2024511799A (ja) * | 2021-03-26 | 2024-03-15 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | ネオアンチゲンワクチンのための方法および化合物 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2022240960A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| CN113264842B (zh) * | 2021-07-21 | 2022-03-01 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| CN115703713B (zh) * | 2021-08-13 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| JP2024534697A (ja) * | 2021-09-14 | 2024-09-20 | レナゲード セラピューティクス マネージメント インコーポレイテッド | 非環状脂質及びその使用方法 |
| US20240335384A1 (en) * | 2021-10-15 | 2024-10-10 | Xiamen Sinopeg Biotech Co., Ltd. | Nitrogen-containing cationic lipid and application thereof |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4452298A4 (en) * | 2021-12-22 | 2025-11-19 | Memorial Sloan Kettering Cancer Center | CELLS EXPRESSING FAS LIGAND AND CFLIP POLYPEPTIDES AND THEIR USES |
| EP4458843A4 (en) * | 2021-12-31 | 2025-07-09 | Guangzhou Nat Laboratory | MRNA VACCINE |
| EP4466283A1 (en) * | 2022-01-21 | 2024-11-27 | T-Knife GmbH | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| PE20242221A1 (es) * | 2022-03-16 | 2024-11-19 | Boehringer Ingelheim Int | Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos |
| CN116655486A (zh) * | 2022-05-19 | 2023-08-29 | 仁景(苏州)生物科技有限公司 | 长链烷基酯胺类化合物及其制备方法和在核酸递送方面的应用 |
| CN115286674A (zh) * | 2022-06-13 | 2022-11-04 | 湖北英纳氏生物科技有限公司 | 一种阳离子脂质体及其制备方法 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| WO2024102332A1 (en) * | 2022-11-07 | 2024-05-16 | Himv Llc | Vaccine compositions comprising a neoantigen of kras |
| WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
| EP4622664A1 (en) * | 2022-11-22 | 2025-10-01 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
| WO2024109866A1 (zh) | 2022-11-24 | 2024-05-30 | 苏州艾博生物科技有限公司 | 提高蛋白表达量的utr分子 |
| EP4640828A1 (en) * | 2022-12-23 | 2025-10-29 | Hanmi Pharm. Co., Ltd. | Antigenic peptide having multiple kras variant peptides linked thereto, nucleic acid encoding the same, and use thereof |
| WO2024147556A1 (ko) * | 2023-01-05 | 2024-07-11 | 의료법인 명지의료재단 | K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물 |
| WO2024151877A2 (en) | 2023-01-11 | 2024-07-18 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| WO2024199359A1 (zh) * | 2023-03-28 | 2024-10-03 | 江苏瑞科生物技术股份有限公司 | 包含环二核苷酸分子的脂质体佐剂系统及其制备方法 |
| WO2024211447A1 (en) * | 2023-04-03 | 2024-10-10 | Chrysalis Biotherapeutics | Tp508 mrnas |
| CN117604031B (zh) * | 2023-04-20 | 2025-05-09 | 龙岩学院 | 一种猫冠状病毒S蛋白mRNA的体外转录系统及其构建方法 |
| TW202530174A (zh) * | 2023-10-19 | 2025-08-01 | 大陸商仁景（蘇州）生物科技有限公司 | 用於遞送的脂質化合物及脂質奈米顆粒 |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025206850A1 (ko) * | 2024-03-29 | 2025-10-02 | 한미약품 주식회사 | 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도 |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| EP0730645A1 (en) | 1993-11-26 | 1996-09-11 | Btg International Limited | Translational enhancer dna |
| WO1996010585A1 (en) | 1994-09-30 | 1996-04-11 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| US6503503B1 (en) | 1997-05-13 | 2003-01-07 | Duke University | Allogeneic cellular vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| US20060009633A9 (en) | 1997-11-13 | 2006-01-12 | Genset, S.A. | Complementary DNAs encoding proteins with signal peptides |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| ES2356934T3 (es) | 2001-06-05 | 2011-04-14 | Curevac Gmbh | ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL. |
| EP2428568B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| AU2002349784A1 (en) | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| EP1556082A1 (en) | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| EP2530157B1 (en) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| EP4174179B1 (en) | 2005-08-23 | 2025-05-07 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| JP5490413B2 (ja) | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| ES2508893T3 (es) | 2006-01-05 | 2014-10-16 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cánceres de estómago |
| CA2638844C (en) | 2006-03-02 | 2016-05-03 | Thomas D. Schmittgen | Microrna expression profile associated with pancreatic cancer |
| BRPI0709340A2 (pt) | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
| JP5520605B2 (ja) | 2006-09-19 | 2014-06-11 | アシュラジェン インコーポレイテッド | 膵臓疾患で差次的に発現されるマイクロｒｎａおよびその使用 |
| WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN101622350A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为干预治疗靶标的miR-126调控基因和通路 |
| WO2008147974A1 (en) | 2007-05-23 | 2008-12-04 | University Of South Florida | Micro-rnas modulating immunity and inflammation |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| JP2010533649A (ja) | 2007-07-13 | 2010-10-28 | ザ ジョンズ ホプキンス ユニバーシティー | Ｂ７−ｄｃ改変体 |
| SI2183361T1 (sl) | 2007-07-27 | 2015-09-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti nevronalnim in možganskim tumorjem |
| PL2201100T3 (pl) | 2007-09-14 | 2016-10-31 | Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu | |
| WO2009046738A1 (en) * | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| AU2008329755A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | MicroRNA expression profiling and targeting in peripheral blood in lung cancer |
| US20110165223A1 (en) | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
| EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| CA2717026A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| JP2011529708A (ja) | 2008-08-04 | 2011-12-15 | ユニバーシティ オブ マイアミ | 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子） |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN102439169B (zh) | 2008-11-13 | 2014-11-19 | 复旦大学 | 用于结肠直肠癌的微rna表达谱分析的组合物和方法 |
| US20120053224A1 (en) | 2008-12-10 | 2012-03-01 | Universitat Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| EP2246433A1 (de) * | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
| WO2010129860A2 (en) | 2009-05-08 | 2010-11-11 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof |
| SG10201912450XA (en) | 2009-06-10 | 2020-03-30 | Arbutus Biopharma Corp | Improved lipid formulation |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| US20130059015A1 (en) | 2010-03-11 | 2013-03-07 | H. Lee Moffitt Cancer Center & Research Institute | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| ES3038392T3 (en) | 2010-05-14 | 2025-10-13 | Massachusetts Gen Hospital | Neoantigen specific cytotoxic t cells for use in treating cancer |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| PT3981427T (pt) * | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| PL4008357T3 (pl) * | 2010-08-31 | 2023-03-06 | Glaxosmithkline Biologicals Sa | Małe liposomy do dostarczania rna kodującego immunogen |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| WO2012055551A2 (de) | 2010-10-26 | 2012-05-03 | Friedrich-Alexander-Universität Erlangen-Nürnberg | NFĸB-SIGNALWEG-MANIPULIERTE DENDRITISCHE ZELLEN |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| EP2944961A1 (en) | 2011-05-06 | 2015-11-18 | XenTech | Markers for cancer prognosis and therapy and methods of use |
| ES2744589T3 (es) | 2011-05-11 | 2020-02-25 | Exosome Diagnostics Inc | Extracción de ácido nucleico de materiales biológicos heterogéneos |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| CN103687957A (zh) * | 2011-05-17 | 2014-03-26 | 现代治疗公司 | 工程化核酸及其用于非人类脊椎动物的方法 |
| PT3892295T (pt) * | 2011-05-24 | 2023-06-01 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| CN103748078B (zh) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | 可裂解脂质 |
| JP5965481B2 (ja) | 2011-07-15 | 2016-08-03 | レオ ファーマ アクティーゼルスカブ | 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の診断用マイクロｒｎａプロファイリング |
| US20150080243A1 (en) | 2011-09-01 | 2015-03-19 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| SG10201903119QA (en) | 2011-09-06 | 2019-05-30 | Agency Science Tech & Res | Polypeptide vaccine |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| CA2856742A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| DE12858350T1 (de) * | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013116126A1 (en) | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| CN103547683A (zh) * | 2012-03-22 | 2014-01-29 | 耶鲁大学 | Kras突变和肿瘤生物学 |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| KR20150004416A (ko) | 2012-04-30 | 2015-01-12 | 글렌 엔. 바버 | 면역 반응의 조절 |
| KR20150006477A (ko) * | 2012-05-09 | 2015-01-16 | 그래댈리스, 인코포레이티드 | 단일-뉴클레오타이드 ｋｒａｓ 돌연변이에 특이적인 이-기능성 짧은-헤어핀 ｒｎａ (ｂｉ-ｓｈｒｎａ) |
| WO2013185052A1 (en) | 2012-06-08 | 2013-12-12 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| AU2013291125A1 (en) * | 2012-07-16 | 2015-01-22 | Dicerna Pharmaceuticals, Inc. | RNAi pharmaceutical composition capable of suppressing expression of KRAS gene |
| WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| US10093701B2 (en) | 2012-09-07 | 2018-10-09 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| EP4483965A3 (en) | 2012-11-28 | 2025-04-02 | BioNTech SE | Individualized vaccines for cancer |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20140234351A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014145038A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Vaccines with biomolecular adjuvants |
| WO2014166501A2 (en) | 2013-04-10 | 2014-10-16 | Skau Aps | Use of immune suppressive peptides as adjuvants |
| CA2908154C (en) | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| SG10201811172PA (en) | 2013-12-09 | 2019-01-30 | Targovax Asa | A peptide mixture |
| EP3094342A4 (en) | 2014-01-15 | 2017-12-27 | Nikolai Khodarev | Anti-tumor therapy |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| CA2942501A1 (en) | 2014-03-17 | 2015-09-24 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| DK3134131T3 (en) * | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| CA2944903A1 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| MX2016014414A (es) * | 2014-05-06 | 2017-02-23 | Targovax Asa | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. |
| PT3766916T (pt) | 2014-06-25 | 2022-11-28 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
| AU2015323736B2 (en) | 2014-09-26 | 2020-09-10 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| WO2016154544A1 (en) | 2015-03-25 | 2016-09-29 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| IL302102A (en) | 2015-05-20 | 2023-06-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| BR112017026709A2 (pt) | 2015-06-11 | 2018-08-28 | Univ Miami | tratamento e diagnóstico de câncer |
| RU2018101225A (ru) * | 2015-06-16 | 2019-07-16 | Тарговакс Аса | Мутированные фрагменты белка ras |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| WO2017015463A2 (en) * | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
| US12150980B2 (en) * | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| EP3328377A4 (en) | 2015-07-31 | 2019-03-13 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES |
| WO2017049245A2 (en) * | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2017062838A1 (en) | 2015-10-07 | 2017-04-13 | Nant Holdings Ip, Llc | Activation of immune-related signalling pathways in cells via optofection |
| US11623001B2 (en) | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| JP2018530620A (ja) | 2015-10-19 | 2018-10-18 | カディラ・ヘルスケア・リミテッド | 同一の分野の発明を含有する新規アジュバント及びワクチン組成物 |
| MA46255A (fr) * | 2015-10-22 | 2019-07-31 | Modernatx Inc | Vaccins anticancéreux |
| LT3368507T (lt) | 2015-10-28 | 2023-03-10 | Acuitas Therapeutics Inc. | Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui |
| EP3393511A1 (en) | 2015-12-21 | 2018-10-31 | La Jolla Institute for Allergy and Immunology | Leveraging immune memory from common childhood vaccines to fight disease |
| CN108472350A (zh) | 2016-01-08 | 2018-08-31 | 瓦西博迪公司 | 新表位rna癌症疫苗 |
| JP2019510488A (ja) | 2016-03-04 | 2019-04-18 | ニューヨーク・ユニバーシティ | 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター |
| WO2017177204A1 (en) | 2016-04-09 | 2017-10-12 | La Jolla Institute For Allergy And Immunology | Leveraging immune memory from common childhood vaccines to fight disease |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| CN109328070A (zh) | 2016-05-04 | 2019-02-12 | 免疫疫苗技术有限公司 | 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法 |
| MX2018014602A (es) | 2016-05-27 | 2019-06-10 | Etubics Corp | Composiciones de vacunas neoepitopos y metodos de uso de las mismas. |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| WO2018015433A2 (en) | 2016-07-20 | 2018-01-25 | Biontech Rna Pharmaceuticals Gmbh | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy |
| EP3503876A4 (en) | 2016-08-23 | 2020-06-10 | Jerome J. Schentag | CHOLESTERYL ESTER VESICLES LOADING PEPTIDES, PROTEINS AND NUCLEIC ACIDS IN CHYLOMICRONS AND BODY CELLS |
| SG11201903674YA (en) * | 2016-10-26 | 2019-05-30 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CA3035591A1 (en) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| WO2018102585A1 (en) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| EA201991804A1 (ru) | 2017-02-01 | 2020-02-07 | МОДЕРНАТиЭкс, ИНК. | ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ |
-
2018
- 2018-02-01 EA EA201991804A patent/EA201991804A1/ru unknown
- 2018-02-01 JP JP2019541287A patent/JP2020514321A/ja active Pending
- 2018-02-01 AU AU2018214556A patent/AU2018214556A1/en not_active Abandoned
- 2018-02-01 WO PCT/US2018/016510 patent/WO2018144775A1/en not_active Ceased
- 2018-02-01 CN CN201880018964.5A patent/CN110430894A/zh active Pending
- 2018-02-01 CA CA3051252A patent/CA3051252A1/en active Pending
- 2018-02-01 SG SG11201906969PA patent/SG11201906969PA/en unknown
- 2018-02-01 EP EP18706040.5A patent/EP3576780A1/en active Pending
- 2018-02-01 MX MX2019009070A patent/MX2019009070A/es unknown
- 2018-02-01 BR BR112019015797-2A patent/BR112019015797A2/pt not_active Application Discontinuation
- 2018-02-01 KR KR1020197025725A patent/KR20190110612A/ko not_active Ceased
- 2018-02-01 CN CN202311184702.5A patent/CN117224710A/zh active Pending
- 2018-02-01 US US16/482,473 patent/US20190351039A1/en not_active Abandoned
-
2019
- 2019-02-19 US US16/279,372 patent/US10881730B2/en active Active
- 2019-07-30 IL IL268361A patent/IL268361A/en unknown
- 2019-07-30 MX MX2022011934A patent/MX2022011934A/es unknown
- 2019-07-30 CL CL2019002134A patent/CL2019002134A1/es unknown
- 2019-08-27 CO CONC2019/0009234A patent/CO2019009234A2/es unknown
-
2020
- 2020-11-18 US US16/951,092 patent/US20210128721A1/en not_active Abandoned
-
2023
- 2023-04-19 JP JP2023068492A patent/JP2023103250A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011934A (es) | 2022-10-20 |
| JP2023103250A (ja) | 2023-07-26 |
| US20190175727A1 (en) | 2019-06-13 |
| CL2019002134A1 (es) | 2019-11-22 |
| CN110430894A (zh) | 2019-11-08 |
| JP2020514321A (ja) | 2020-05-21 |
| BR112019015797A2 (pt) | 2020-03-17 |
| CN117224710A (zh) | 2023-12-15 |
| AU2018214556A1 (en) | 2019-08-15 |
| US20210128721A1 (en) | 2021-05-06 |
| MX2019009070A (es) | 2019-10-30 |
| CA3051252A1 (en) | 2018-08-09 |
| KR20190110612A (ko) | 2019-09-30 |
| US20190351039A1 (en) | 2019-11-21 |
| EP3576780A1 (en) | 2019-12-11 |
| EA201991804A1 (ru) | 2020-02-07 |
| US10881730B2 (en) | 2021-01-05 |
| SG11201906969PA (en) | 2019-08-27 |
| WO2018144775A1 (en) | 2018-08-09 |
| CO2019009234A2 (es) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268361A (en) | Therapeutic immunomodulatory mRNA preparations encoding oncogenic mutation peptides | |
| PT3463465T (pt) | Exossomas que compreendem polipéptidos terapêuticos | |
| PL3298043T3 (pl) | Kompozycje polipeptydów SIRP i sposoby zastosowania | |
| IL273961A (en) | Polypeptide compositions containing spacers | |
| IL265463A (en) | Therapeutic peptides related to mots-c | |
| GB201620376D0 (en) | Crack resistant cement composition | |
| IL268648B (en) | Therapeutic dendrimers | |
| SG11202000650YA (en) | Factor viii (fviii) gene therapy methods | |
| AU201813347S (en) | Trowel | |
| GB201700557D0 (en) | Novel peptides | |
| SG11202005653RA (en) | Novel peptide | |
| GB2537548B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| EP3399990A4 (en) | THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF | |
| IL271625A (en) | Insulated concrete structure | |
| GB2551275B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| GB201703529D0 (en) | Vaccine composition | |
| GB201617470D0 (en) | Novel therapy | |
| HK40016403A (en) | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides | |
| GB2551279B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| DK3579865T3 (en) | Therapeutic compositions | |
| IL268046B1 (en) | Therapeutic peptides | |
| GB201713811D0 (en) | Therapeutic compositions | |
| GB201708477D0 (en) | Therapeutic compositions | |
| GB201706281D0 (en) | Therapeutic compositions | |
| GB201813783D0 (en) | Therapeutic compositions |